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OBJECTIVE: An elevated red cell distribution width has been recognized as a predictor of various cardiovascular
diseases. Slow coronary flow syndrome is an important angiographic clinical entity with an unknown etiology.
This study aimed to examine the relationship between red cell distribution width and the presence of slow
coronary flow syndrome.
METHODS: In total, 185 patients with slow coronary flow syndrome and 183 age- and gender-matched subjects
with normal coronary flow (controls) were prospectively enrolled in this study. Red cell distribution width and
C-reactive protein were measured upon admission, and the results were compared between the patients with
slow coronary flow syndrome and normal controls.
RESULTS: Red cell distribution width levels were significantly higher in the patients with slow coronary flow
syndrome than the normal controls. Moreover, the data showed that the plasma C-reactive protein levels were
also higher in the patients with slow coronary flow syndrome than in the normal controls. In addition, a
multivariate analysis indicated that C-reactive protein and red cell distribution width were the independent
variables most strongly associated with slow coronary flow syndrome. Finally, the red cell distribution width
was positively correlated with C-reactive protein and mean thrombosis in the myocardial infarction frame
counts of the patients with slow coronary flow syndrome.
CONCLUSION: The data demonstrated that red cell distribution width levels are significantly higher and
strongly positively correlated with both C-reactive protein and thrombosis in the myocardial infarction frame
counts of patients with slow coronary flow syndrome. These findings suggest that red cell distribution width
may be a useful marker for patients with slow coronary flow syndrome.
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Inflammation.
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& INTRODUCTION
Slow coronary flow syndrome (SCFS) is an angiographic
observation characterized by angiographically normal or near-
normal coronary arteries with the delayed progression of
contrast dye injected into the coronary tree (1-3). Despite the
relatively good prognosis of SCFS patients, the chronic nature
of the persistent chest discomfort can significantly impair
quality of life (1). In addition, many SCFS patients suffer from
recurrent chest pain, resulting in emergency room evaluations,
hospitalizations, and repeat cardiac catheterizations, accord-
ing to a previous study (2). More importantly, life threatening
arrhythmias and sudden cardiac death have also been
reported in these patients (3). Although intensive studies have
been performed over the past several decades, the underlying
mechanism responsible for SCFS remains unknown (1-3).
Red cell distribution width (RDW), a part of a routine
complete blood count, measures the variability in the size of
circulating erythrocytes, which has been utilized in the
differential diagnosis of anemia (4,5). Recently, elevated
RDW levels have been suggested as a readily available
marker for and independent predictor of various cardio-
vascular diseases, including acute and chronic arterial
diseases (6-10), percutaneous coronary intervention after
acute myocardial infarction (11,12), and heart failure (13,14)
in the elderly and general populations (15,16).
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It has been reported that inflammation may be a potential
mechanism underlying elevated RDW levels in patients
with chronic and acute cardiovascular diseases (6-14).
Additionally, emerging data have suggested that inflamma-
tion may play a role in the pathogenesis of SCFS (3).
Accordingly, we hypothesized that an elevated RDW level
might be significantly associated with the presence of SCFS
because of the inflammatory features of this unique
disorder. Therefore, in the present study, we prospectively
examined the relationship between RDW levels and the
presence of SCFS.
& METHODS
Subjects
This observational study was derived from a cohort of
patients prospectively entered into a database. The purpose
was to assess the prognostic significance of various plasma
biomarkers in patients with known or suspected coronary
artery disease in our divisions at the Fu Wai and Anzhen
Hospitals Beijing. The study was approved by the local
ethics committee and complied with the Declaration of
Helsinki. The study population was selected between
December 2009 and March 2012 based on the presence of
angina-like chest pain or a positive treadmill exercise test.
Finally, 185 consecutive SCFS patients and 183 age- and
gender-matched normal controls were enrolled. The inclu-
sion criteria were patients with angiographically proven
normal coronary arteries and slow flow in at least one of
three main coronary arteries (SCFS group, 159 males and 26
females, mean age 46¡10 years), and 183 subjects with
angiographically proven normal coronary arteries with
normal coronary flow ([NCF] group, 162 males and 21
females, mean age 44¡8 years) were also included.
All subjects enrolled in this study had normal hepatic and
renal function. Current smoking, hypertension, diabetes
mellitus, and hyperlipidemia were defined according to
past literature reports (4-7). The following exclusion criteria
were applied: evidence of coronary artery disease, myocar-
dial infarction, valvular heart disease, congestive heart
failure, left ventricular dysfunction, and echocardiographi-
cally proven left ventricular hypertrophy, or a history of
dysphagia, swallowing and intestinal motility disorders,
untreated thyroid disease, sinus node dysfunction or
conduction disturbance, estrogen replacement therapy,
carcinoma, poorly controlled hypertension (systolic blood
pressure .160 mmHg or diastolic blood pressure
.105 mmHg), a recent major operation (,3 months),
autoimmune disease, or metabolic syndrome. In addition,
patients with previous histories of anemia and those who
had received previous red blood cell transfusions or were
being treated for anemia (e.g., with supplemental iron,
folate, or an erythropoiesis-stimulating agent) were not
included in this study. Patients with known hematological
disease, such as hemolytic anemia, neoplastic metastases to
the bone marrow, or iron replacement therapy, which could
increase plasma RDW levels, were also excluded.
The baseline characteristics of all enrolled subjects
were recorded, including age, gender, body mass index
(BMI), diabetes mellitus, hypertension, dyslipidemia,
smoking, family history of coronary artery disease, left
ventricular ejection fraction, creatinine level, and current
medications.
Coronary angiography
Elective coronary angiography was performed for all
enrolled patients using the standard Judkins technique, and
the results were analyzed by at least two interventional
physicians, as in our previous study (17). Only angiograms
with visually smooth contours with no wall irregularities
were considered to be normal. Iopromide was used as a
contrast in the angiography (Ultravist-370, Schering AG,
Berlin, Germany).
Assessment of coronary blood flow
The coronary flow rates of all subjects were determined
by the thrombosis in myocardial infarction (TIMI) frame
counts (TFCs) because the method is a simple, reproducible,
objective, and quantitative index of coronary flow velocity
(18). A TFC was determined for each major coronary artery
in each patient and control subject according to the method
first described by Gibson et al. (18). Briefly, the number of
cineangiographic frames (recorded at 30 frames per second)
required for the leading edge of the column of radiographic
contrast to reach a predetermined landmark is determined.
The first frame is defined as the frame in which the
concentrated dye occupies the full width of the proximal
coronary artery lumen, touching both borders of the lumen
and exhibiting forward motion in the artery. The final frame
is designated when the leading edge of the contrast column
initially arrives at the distal landmark. In the left anterior
descending (LAD) coronary artery, the landmark used is the
most distal branch nearest the apex of the left ventricle,
commonly referred to as a ‘‘pitchfork’’. All antianginal and
anti-ischemic medications, except for sublingual nitrogly-
cerin, were withheld for at least 24 hours before the
examination. To exclude the possibility of a coronary spasm
during coronary angiography, all patients underwent
hyperventilation tests, which were performed by asking
the patients to breathe quickly and deeply for at least five
minutes.
The mean TFC for each patient and control subject was
calculated by adding the TFCs of the LAD artery, left
circumflex artery (LCX), and right coronary artery (RCA)
and then dividing the sum by three. All participants with a
TFC .27 were diagnosed with SCFS (18). The mean TFCs
reported by the two independent observers were compared
to assess inter-observer reliability. A discrepancy was
subsequently resolved by a third observer. For the first 30
coronary angiograms, the reviewing process was repeated
at the end of the study to determine intra-observer
variability.
Determinations of RDW and C-reactive protein
(CRP)
Erythrocyte count, hemoglobin, RDW, corpuscular
volume, and white blood cell (WBC) count were determined
using the automated hematology analyzer XE-1200 (Sysmex,
Kobe, Japan). The normal range of RDW (%) in our
laboratory was 10-16%. The other biochemical measure-
ments were performed using a molecular analyzer (Roche
Diagnostics, Manheim, Germany).
EDTA-anticoagulated peripheral blood samples were
collected after a 12-hour overnight fast at baseline (before
the coronary angiography). The plasma was obtained after
centrifugation at 3000 rpm at 4 C˚ for 15 minutes. The
levels of high-sensitivity CRP were determined using
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immunoturbidimetry (Beckmann Assay 360), as in our
previous study (17). The median normal CRP value was
0.08 mg/dL, with 90% of normal values ,0.03 mg/dL and
with a lower detection limit of 0.02 mg/dL. The inter-assay
and intra-assay coefficients of variation were 4.5% and
5.0%, respectively. Finally, to assess the potential relation-
ship between RDW levels and TFCs or CRP, a correlation
analysis was performed for patients with SCFS.
Statistical analysis
The continuous variables are expressed as the mean¡
standard deviation (SD), and the categorical variables are
expressed as percentages. A comparison of continuous
variables between the two groups was performed using
Student’s t-test and/or the Mann-Whitney U-test. The chi-
squared test or Fisher’s exact test was used to compare the
categorical variables between the two groups. Because the
CRP distribution is skewed rightward, a log transformation
was performed at baseline, and the significance of any
difference in the distributions was assessed with the
Wilcoxon rank-sum test, as in our previous study (17).
Univariate and multivariate analyses were used for the
baseline clinical characteristics, inflammatory biomarkers,
and RDW. The association between RDW and CRP or TFC
was tested using Spearman’s correlation coefficient. The
SCFS patients were divided into three groups using the
upper tertile of the baseline RDW and CRP values as a
prespecified cutoff (RDW, 13.8% and CRP, 3 mg/dL). A
p-value ,0.05 was considered statistically significant.
& RESULTS
Baseline clinical characteristics
The baseline clinical characteristics of the SCFS patients
(n = 185) or the age- and gender-matched normal controls
(n = 183) are summarized in Table 1. There were no
significant differences between the SCFS group and the
controls in the following baseline clinical variables: age,
BMI, family history of coronary artery disease, left ventricle
function, the mean diameter of the coronary arteries, and
medications. However, the risk factors for cardiovascular
disease, such as current smoking, hypertension, dyslipide-
mia, and diabetes, were higher in the SCFS patients than in
the normal controls, although a higher TFC was found in the
SCFS patients (Table 1).
Laboratory findings
As shown in Table 2, there were no differences in laboratory
variables, including erythrocyte count, mean corpuscular
volume, hemoglobin, and creatinine, between the two groups.
However, the WBC counts, monocyte counts, and plasma CRP
levels were higher in the SCFS patients than in the controls
(WBC count, 6836¡1130/mm3 versus 6327¡1092/mm3,
p= 0.047; monocyte count, 641¡162/mm3 versus 609¡147/
mm3, p= 0.035; CRP level, 0.29¡0.16 mg/L versus
0.21¡0.14 mg/L, p= 0.042). In addition, the pattern of the
RDW levels was similar to the pattern of the CRP levels, with
elevated RDW levels in the SCFS patients compared to the
controls (13.5¡1.8 versus 12.8¡1.6, p= 0.031).
Univariate and multivariate analyses
In this study, the seven variables associated with SCFS,
including smoking, hypertension, dyslipidemia, diabetes,
peripheral circulating WBCs, monocytes, CRP and RDW
(p,0.05 in the univariate analysis) are presented in Table 3
(smoking, odds ratio [OR] 1.354, 95% confidence interval
Table 1 - Baseline clinical characteristics (mean¡SD).
Variables SCFS group NCF group p-value
(n= 185) (n = 183)
Age (years) 46¡10 44¡8 0.312
Male/female 159/26 162/21 0.409
Body mass index (kg/m2) 23¡6 22¡4 0.055
Family history of CAD, n (%) 21 (11.4) 19 (10.4) 0.268
Current smoker, n (%) 46 (24.9) 28 (15.4) 0.037
Hypertension, n (%) 68 (36.8) 35 (19.1) 0.013
Dyslipidemia, n (%) 39 (21.1) 25 (13.7) 0.058
Diabetes, n (%) 15 (8.1) 7 (3.5) 0.050
LVEF (%) 61¡9 62¡6 0.182
Medications
Aspirin, n (%) 159 (85.9) 150 (82.0) 0.493
b-blocker, n (%) 47 (25.4) 26 (14.2) 0.042
ACEI, n (%) 52 (28.1) 44 (24.0) 0.509
Statin, n (%) 36 (19.5) 19 (10.4) 0.186
CCB, n (%) 23 (17.8) 17 (9.4) 0.08
SCFS = slow coronary flow syndrome; NCF=normal coronary flow;
CAD= coronary artery disease; LVEF = left ventricular ejection fraction;
ACEI = angiotensin-converting enzyme inhibitor; CCB= calcium channel
blocker.
Table 2 - Laboratory findings (mean¡SD).
Variables SCFS group NCF group p-value
(n = 185) (n = 183)
hs-CRP (mg/dL) 0.29¡0.16 0.21¡0.14 0.042
RDW (%) 13.5¡1.8 12.7¡1.5 0.031
White blood cell count
(/mm3)
6836¡1130 6327¡1092 0.047
Monocyte count (/mm3) 641¡162 609¡147 0.035
Erythrocyte count (1012/L) 4.3¡0.6 4.3¡0.5 0.427
Mean corpuscular
volume (fL)
83¡4.6 85¡4.3 0.388
Hemoglobin (g/dL) 13.6¡1.4 13.5¡1.5 0.324
Creatinine (mg/dL) 1.3¡0.4 1.3¡0.4 0.562
Vascular diameter (mm) 3.23¡0.36 3.21¡0.40 0.712
TFC 51.7¡15.5 38.8¡6.4 0.018
SCFS = slow coronary flow syndrome; NCF=normal coronary flow; Hs-CRP=high-sensitivity C-reactive protein; RDW= red cell distribution width;
TFC= thrombolysis in myocardial infarction frame count.
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[CI], 1.081-1.593, p= 0.031; diabetes, OR 1.286, 95% CI, 1.052-
1.476, p= 0.046; hypertension, OR 1.277, 95% CI, 1.048-1.432,
p= 0.050; WBCs, OR 1.287, 95% CI, 1.071-1.840, p= 0.051;
monocytes, OR 1.426, 95% CI, 1.157-1.885, p= 0.041; CRP,
OR 1.901, 95% CI, 1.292-3.127, p= 0.015; RDW, OR 1.962,
95% CI, 1.319-3.348, p= 0.003). We then included these seven
variables in a multivariate analysis. Interestingly, we found
that RDW (tertile, .13.8%) and CRP (tertile, .3 mg/dL)
were the independent variables most strongly associated
with SCFS (RDW, OR 3.973, 95% CI, 1.352-4.262, p= 0.001;
CRP, OR 3.112, 95% CI, 1.226-3.633, p= 0.018; Table 4).
Correlation between RDW and CRP or TFC
A linear correlation analysis was first performed to
determine the relationship between the RDW and CRP
levels in the SCFS patients. In addition, the correlation
between the RDW and mean TFCs was also analyzed. A
significantly positive correlation between the RDW levels
and CRP (Figure 1, n = 185, c= 0.382, p= 0.014) or mean TFCs
(Figure 2, n = 185, c= 0.531, p= 0.001) was detected.
& DISCUSSION
In the present study, we demonstrated for the first time
that higher RDW levels exist in SCFS patients. In addition,
the data showed that baseline RDW levels are an indepen-
dent predictor of this unique disorder. Finally, our study
indicated that there is a strongly positive correlation
between the RDW levels and CRP or TFCs in patients with
SCFS. Taken together, the results of the present study
indicate that RDW may be a useful marker for detecting the
presence of SCFS.
SCFS was first described as early as 1972. A limited
number of studies have focused on the etiology of this
uncommon angiographic phenomenon since that time, and
the pathophysiological mechanism of SCFS remains largely
unclear; however, several potential hypotheses have been
suggested, such as the organic or functional dysfunction of
small coronary arteries, an earlier form of atherosclerosis,
platelet aggregability, and an imbalance between vasocon-
stricting and vasodilating factors (3). Inflammation has been
considered to be a major contributing factor in many
cardiovascular events and is associated with different
clinical settings of coronary artery disease, which may be
involved in SCFS development. In fact, Turhan et al. found
that serum intercellular adhesion molecule-1 (ICAM-1),
vascular cell adhesion molecule-1 (VCAM-1), and E-selectin
levels were higher in SCFS patients than in NCF patients.
Moreover, these increased soluble ICAM-1, VCAM-1, and E-
selectin levels were significantly correlated with average
TFCs in SCFS patients (19). Our previous study also
demonstrated that increased plasma IL-6 levels were related
to the presence of SCFS (20). Therefore, we hypothesized
that SCFS might be a syndrome that is strongly associated
with an inflammatory response (3,20).
An increased RDW results from heterogeneity in the size
of erythrocytes and erythrocyte fragmentation in the
circulation. The RDW is generally used in combination
with the mean corpuscle volume as an indicator in the
differential diagnosis of anemia (21). Factors that contribute
to the increased heterogeneity of erythrocyte size include
iron or vitamin B12/folate deficiency, decreased erythrocyte
lifespan, impaired erythropoiesis, and factors that contri-
bute to erythrocyte fragmentation, including increased
Table 3 - Multivariate analysis of variables linked to SCFS.
Variables
Chi-squared
test p value OR 95% CI
Smoking 3.283 0.031 1.354 1.081-1.593
Diabetes 3.057 0.046 1.286 1.052-1.476
Hypertension 2.974 0.050 1.277 1.048-1.432
WBC count 3.127 0.051 1.287 1.071-1.840
PMC 3.628 0.041 1.426 1.157-1.885
CRP 4.201 0.015 1.901 1.292-3.127
RDW 4.831 0.003 1.962 1.319-3.348
SCFS = slow coronary flow syndrome; WBC=white blood cell;
PMC=peripheral monocyte count; CRP=C-reactive protein; RDW= red
cell distribution width.
Table 4 - Adjusted odds ratios for SCFS in the upper tertile
of CRP and RDW.
Tertile Chi-squared test p-value OR 95% CI
CRP (.3 mg/dL) 4.350 0.001 3.112 1.226-3.633
RDW (.13.8%) 5.424 0.018 3.973 1.352-4.262
CRP=C-reactive protein; RDW= red cell distribution width.
Figure 1 - Correlation of RDW levels and plasma CRP concentra-
tions in patients with SCF. There was a positive correlation
between the RDW levels and CRP concentrations (n = 185,
c=0.382, p=0.014).
Figure 2 - Correlation of RDW levels and in TFCs in patients with
SCF. There was a positive correlation between the RDW levels
and TFC (n=185, c=0.531, p=0.001).
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fragility and the destruction of red blood cells (22,23).
Recently, an elevated RDW was found to be a strong and
independent predicator of an increased risk of mortality and
adverse cardiovascular outcomes in patients with acute and
chronic cardiac conditions (4-16). Although these studies
demonstrated the role of RDW in a variety of cardiovascular
diseases, the association between RDW levels and SCFS has
not yet been assessed. In the present study, we elaborated
on the results of previous studies and found, for the first
time, that RDW is significantly higher in SCFS patients than
in normal controls (13.5¡1.8 versus 12.8¡1.6, p= 0.031). A
multivariate analysis showed that the upper tertile of RDW
(.13.8%) was an independent predictor of SCFS (OR 3.973,
95% CI 1.352-4.262, p= 0.018). Our data may provide
information regarding the role of RDW in cardiovascular
diseases.
The exact mechanism underlying the correlation between
higher levels of RDW and the presence of SCFS is relatively
unknown. One of the most likely mechanisms is inflamma-
tion. In fact, recent findings have suggested that inflamma-
tion may play a pathogenic role in SCFS (3). A higher RDW
was associated with inflammatory markers, such as soluble
tumor necrosis factor receptors and CRP, in atherosclerosis
and other chronic diseases (21,22). A strong association
between RDW and inflammatory markers was found in a
large cohort of unselected adult outpatients and in patients
with inflammatory bowel disease (23). Proinflammatory
cytokines may also contribute to the heterogeneity of the
erythrocyte population through other pathways, such as
oxidative stress (24). Red blood cells have a large anti-
oxidant capacity and serve as a primary oxidative sink, but
these cells are prone to oxidative damage, which reduces
cell survival and induces the release of juvenile erythrocytes
into the circulation (25). In the present study, the data first
demonstrated that elevated plasma CRP was higher in the
SCFS patients compared with the normal controls
(0.29¡0.16 mg/L versus 0.21¡0.14 mg/L, p = 0.042). A
positive correlation between RDW and plasma CRP or
TFCs was then found in the SCFS patients, thereby
suggesting that an inflammatory mechanism may be
involved in higher RDW levels in SCFS patients.
In conclusion, in this prospective, age- and gender-
matched case-control study, the data demonstrated, for the
first time, that RDW levels are higher and positively
correlated with CRP and TFC in SCFS patients. This finding
suggests that RDW may be a useful marker and predictor
for SCFS.
& LIMITATIONS
The small sample size may be a study limitation. Other
factors, including iron, vitamin B12, and folate, were not
measured in this study.
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